Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors

NCT01401868 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT01401868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01401868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2011
Completion date
January 31, 2013
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors